» Articles » PMID: 16570345

Identification of Serum Proteins Discriminating Colorectal Cancer Patients and Healthy Controls Using Surface-enhanced Laser Desorption Ionisation-time of Flight Mass Spectrometry

Overview
Specialty Gastroenterology
Date 2006 Mar 30
PMID 16570345
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To detect the new serum biomarkers for colorectal cancer (CRC) by serum protein profiling with surface-enhanced laser desorption ionisation--time of flight mass spectrometry (SELDI-TOF MS).

Methods: Two independent serum sample sets were analysed separately with the ProteinChip technology (set A: 40 CRC+49 healthy controls; set B: 37 CRC+31 healthy controls), using chips with a weak cation exchange moiety and buffer pH 5. Discriminative power of differentially expressed proteins was assessed with a classification tree algorithm. Sensitivities and specificities of the generated classification trees were obtained by blindly applying data from set A to the generated trees from set B and vice versa. CRC serum protein profiles were also compared with those from breast, ovarian, prostate, and non-small cell lung cancer.

Results: Mass-to-charge ratios (m/z) 3.1x10(3), 3.3x10(3), 4.5x10(3), 6.6x10(3) and 28x10(3) were used as classifiers in the best-performing classification trees. Tree sensitivities and specificities were between 65% and 90%. Most of these discriminative m/z values were also different in the other tumour types investigated. M/z 3.3x10(3), main classifier in most trees, was a doubly charged form of the 6.6x10(3)-Da protein. The latter was identified as apolipoprotein C-I. M/z 3.1x10(3) was identified as an N-terminal fragment of albumin, and m/z 28x10(3) as apolipoprotein A-I.

Conclusion: SELDI-TOF MS followed by classification tree pattern analysis is a suitable technique for finding new serum markers for CRC. Biomarkers can be identified and reproducibly detected in independent sample sets with high sensitivities and specificities. Although not specific for CRC, these biomarkers have a potential role in disease and treatment monitoring.

Citing Articles

Top-Down Proteomics Identifies Plasma Proteoform Signatures of Liver Cirrhosis Progression.

Forte E, Sanders J, Pla I, Kanchustambham V, Hollas M, Huang C Mol Cell Proteomics. 2024; 23(12):100876.

PMID: 39521382 PMC: 11664408. DOI: 10.1016/j.mcpro.2024.100876.


Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy.

Li Z, Chen J, Xu B, Zhao W, Zha H, Han Y Clin Proteomics. 2024; 21(1):35.

PMID: 38764042 PMC: 11103996. DOI: 10.1186/s12014-024-09483-8.


Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance).

Quintanilha J, Sibley A, Liu Y, Niedzwiecki D, Halabi S, Rogers L BMC Genomics. 2024; 25(1):473.

PMID: 38745123 PMC: 11092225. DOI: 10.1186/s12864-024-10354-7.


Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.

Patel K, Kashfi K Biochem Pharmacol. 2021; 196:114654.

PMID: 34129857 PMC: 8665945. DOI: 10.1016/j.bcp.2021.114654.


Comprehensive aptamer-based screen of 1317 proteins uncovers improved stool protein markers of colorectal cancer.

Li H, Vanarsa K, Zhang T, Soomro S, Cicalese P, Duran V J Gastroenterol. 2021; 56(7):659-672.

PMID: 34117903 DOI: 10.1007/s00535-021-01795-y.


References
1.
Kim S, Fernandes L, Saad S, Matos D . Assessment of the value of preoperative serum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients. Int J Biol Markers. 2003; 18(3):182-7. DOI: 10.1177/172460080301800305. View

2.
Yu J, Chen Y, Zheng S . An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J Gastroenterol. 2004; 10(21):3127-31. PMC: 4611255. DOI: 10.3748/wjg.v10.i21.3127. View

3.
Tachibana M, Ohkura Y, Kobayashi Y, Sakamoto H, Tanaka Y, Watanabe J . Expression of apolipoprotein A1 in colonic adenocarcinoma. Anticancer Res. 2003; 23(5b):4161-7. View

4.
Zhao G, Gao C, Song G, Li D, Wang X . [Identification of colorectal cancer using proteomic patterns in serum]. Ai Zheng. 2004; 23(6):614-8. View

5.
Allard L, Lescuyer P, Burgess J, Leung K, Ward M, Walter N . ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics. 2004; 4(8):2242-51. DOI: 10.1002/pmic.200300809. View